Researchers from the Michigan State University have studied a new class of drugs for the treatment of breast and lung cancer. Results published recently in the journal “Cancer Prevention Research” show that the drug can inhibit the expression of certain growth-promoting genes, thereby suppressing tumor growth. Further studies are underway and the drug is currently under clinical trial. Researchers were particularly interested in targeting the Bromodomain And Extraterminal (BET) proteins.
I-BET 762 is a new bromodomain inhibitor that targets BET proteins and interrupts further transcription of oncogenes and c-Myc, pSTAT3, and pERK protein expression. So far, the drug has shown promising results in inhibiting the growth of cancerous cells in lung and breast cancer both in vivo and in vitro. In another independent study, researchers have shown that I-BET 762 is also useful in reducing…
